Skip Links

Notes to the Financial Statements (Group)

27 Statutory and other information

2009
$m
2008
$m
2007
$m
Fees payable to KPMG Audit Plc and its associates:
Group audit fee 2.4 3.2 3.6
Fees payable to KPMG Audit Plc and its associates for other services:
The audit of subsidiaries pursuant to legislation 6.6 7.1 6.1
Other services pursuant to legislation 2.9 3.3 3.6
Taxation 1.0 0.9 1.1
All other services 0.7 1.7 0.7
Fees payable to KPMG Audit Plc in respect of the Group's pension schemes:
The audit of subsidiaries' pension schemes 0.5 0.6 0.6
14.1 16.8 15.7

Other services pursuant to legislation includes fees of $2.3m (2008: $2.5m; 2007: $2.7m) in respect of section 404 of the Sarbanes-Oxley Act.

Taxation services consist of tax compliance services and, to a lesser extent, tax advice.

All other services includes assurance services in relation to third party compliance with manufacturing and distribution agreements and advisory services supporting management in their development of competency and development frameworks for staff.

Related party transactions

The Group had no material related party transactions which might reasonably be expected to influence decisions made by the users of these Financial Statements.

Key management personnel compensation

Key management personnel are defined for the purpose of disclosure under IAS 24 'Related Party Disclosures' as the Board of Directors and the SET.

2009
$000
2008
$000
2007
$000
Short-term employee benefits 20,784 21,973 31,525
Post-employment benefits 2,080 2,290 2,072
Termination benefits 3,639 - -
Share-based payments 12,547 13,210 11,515
39,050 37,473 45,112

Short-term employee benefits in 2007 include one-off employee costs of $11m in relation to the acquisition of MedImmune.

Total remuneration is included within employee costs (see Note 24).

Subsequent events

There were no material subsequent events.

Financial
Review

"Looking forward, our plans to manage the business ... should generate strong cash flow to provide for the needs of the business and shareholder returns."

Find out more

Download
Report

AstraZeneca Annual Report and Form 20-F Information 2009

English (PDF 5.8Mb)
Swedish (PDF 3.3Mb)